Wielka Brytania - angielski - MHRA (Medicines & Healthcare Products Regulatory Agency)

medicom healthcare ltd - chloramphenicol - eye ointment - 10mg/1gram

Republika Południowej Afryki - angielski - South African Health Products Regulatory Authority (SAHPRA)

pharmacare limited û woodmead - ointment - see ingredients - each 5 g ointment contains clobetasol propionate 2,5 mg

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone 0.8 mg - kaitlib™ fe (norethindrone and ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets) is indicated for use by women to prevent pregnancy. the efficacy of kaitlib fe in women with a body mass index (bmi) of > 35 kg/m2 has not been evaluated. do not prescribe kaitlib fe to women who are known to have the following: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to:     o    smoke, if over age 35 [see  boxed  warning , and  warnings  and  precautions  (5.1.)]     o     have deep vein thrombosis or pulmonary embolism, now or in the past [see  warnings  and  precautions  (5.1)]     o    have cerebrovascular disease [see  warnings  and  precautions  (5.1)]     o    have coronary artery disease [see  warnings  and  precautions  (5.1)]     o    have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see  warnings  and  precautions  (5.1)]

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

lupin limited - norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - norethindrone 0.8 mg - kaitlib™ fe (norethindrone and ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets) is indicated for use by women to prevent pregnancy. the efficacy of kaitlib fe in women with a body mass index (bmi) of > 35 kg/m2 has not been evaluated. do not prescribe kaitlib fe to women who are known to have the following: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to:     o    smoke, if over age 35 [see  boxed  warning , and  warnings  and  precautions  (5.1.)]     o     have deep vein thrombosis or pulmonary embolism, now or in the past [see  warnings  and  precautions  (5.1)]     o    have cerebrovascular disease [see  warnings  and  precautions  (5.1)]     o    have coronary artery disease [see  warnings  and  precautions  (5.1)]     o    have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see  warnings  and  precautions  (5.1)]

Stany Zjednoczone - angielski - NLM (National Library of Medicine)

lupin pharmaceuticals, inc. - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), norethindrone (unii: t18f433x4s) (norethindrone - unii:t18f433x4s) - kaitlib™ fe (norethindrone and ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets) is indicated for use by women to prevent pregnancy. the efficacy of kaitlib fe in women with a body mass index (bmi) of > 35 kg/m2 has not been evaluated. kaitlib fe (norethindrone and ethinyl estradiol chewable tablets and ferrous fumarate chewable tablets) is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to:     o    smoke, if over age 35 [see  boxed  warning , and  warnings  and  precautions  (5.1.)]     o     have deep vein thrombosis or pulmonary embolism, now or in the past [see  warnings  and  precautions  (5.1)]     o    have cerebrovascular disease [see  warnings  and  precautions  (5.1)]     o    have coronary artery disease [see  warnings  and  precautions  (5.1)]     o    have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see  warnings  and  precautions  (5.1)]     o    have inherited or acquired hypercoagulopathies [see  warnings  and  precautions  (5.1)]     o    have uncontrolled hypertension [see  warnings  and  precautions  (5.5)]     o    have diabetes with vascular disease [see  warnings  and  precautions  (5.7)]     o    have headaches with focal neurological symptoms or have migraine headaches with or without aura if over age 35 [see  warnings  and  precautions  (5.8)] - current diagnosis of, or history of, breast cancer, which may be hormone-sensitive [see warnings and precautions (5.2)] - liver tumors, benign or malignant, or liver disease [see warnings and precautions (5.3) , use in specific populations (8.7) , and clinical pharmacology (12.3)] - undiagnosed abnormal uterine bleeding [see warnings and precautions (5.9)] - use of hepatitis c drug combinations containing ombitasvir/paritaprevir/ritonavir, with or without dasabuvir, due to the potential for alt elevations [see warnings and precautions (5.4)] risk summary there is no use for contraception in pregnancy; therefore, kaitlib fe should be discontinued during pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or nongenital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to cocs before conception or during early pregnancy. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively. risk summary contraceptive hormones and/or metabolites are present in human milk. cocs can reduce milk production in breast-feeding females. this reduction can occur at any time but is less likely to occur once breast-feeding is well-established. when possible, advise the nursing female to use other methods of contraception until she discontinues breast-feeding [see dosage and administration (2.2) ]. the developmental and health benefits of breast-feeding should be considered along with the mother's clinical need for kaitlib fe and any potential adverse effects on the breast-fed child from kaitlib fe or from the underlying maternal condition. safety and efficacy of kaitlib fe have been established in women of reproductive age. efficacy is expected to be the same in postpubertal adolescents under the age of 18 years as for users 18 years and older. use of this product before menarche is not indicated. kaitlib fe have not been studied in postmenopausal women and is not indicated in this population. the pharmacokinetics of kaitlib fe has not been studied in subjects with renal impairment. no studies have been conducted to evaluate the effect of hepatic disease on the disposition of kaitlib fe. however, steroid hormones may be poorly metabolized in patients with impaired liver function. acute or chronic disturbances of liver function may necessitate the discontinuation of coc use until markers of liver function return to normal [see  contraindications  (4) , and  warnings  and  precautions  (5.3)]. the safety and efficacy of kaitlib fe in women with a bmi > 35 kg/m2 have not been evaluated.

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

philip n & stacie h robins - chlorfluazuron - bait - chlorfluazuron uron active 1.0 g/kg - insecticide - bridges | commercial premises - general | food preparation and serving areas | landscape structures | pest control - along fence - subterranean termite ex. m. darwiniensis | coptotermes spp. | schedorhinotermes spp.

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

4 farmers australia pty ltd - sodium fluoroacetate - bait - sodium fluoroacetate mineral-fluorine active 0.4 g/kg - vertebrate poison - animal pest control - rabbit

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

zapi s.p.a - brodifacoum - bait - brodifacoum coumarin active 0.05 g/kg - vertebrate poison - agricultural/farm buildings | commercial/industrial premises | domestic premises | public premises | animal housing | food prepa - rodent, rat or mouse | black rat/mouse | brown rat/mouse | mouse | rat | rodent | roof rat

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

pct holdings pty ltd - bromadiolone - bait - bromadiolone coumarin active 0.05 g/kg - vertebrate poison - agricultural area - general | commercial premises - general | industrial and/or domestic premises | factory | in and around | in - mouse - mus spp. | rat

Australia - angielski - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sumitomo chemical australia pty. limited - pyriproxyfen - bait - pyriproxyfen pyridine active 5.0 g/kg - insecticide - citrus fruit orchard | commercial/industrial land | crop - spice | cropping area | domestic and/or public area | fruit | garden - invasive & nuisance ants -refer to alias | bigheaded ant | black ants | green tree ants | longlegged ants | meat ants | pennant ants | pony ants | red imported fire ant | singapore ant | sugar ants | tropical fire ant | tyrant ants | yellow crazy ant